Retatrutide Pen (Revion+)

Description 

Retatrutide is a synthetic research compound investigated for its activity at GLP-1, GIP, and glucagon receptors. This 40mg pre-filled research pen is supplied ready-to-use to support controlled dosing in laboratory and research settings.

• Chronic Weight Management: Its most prominent investigated use is for the treatment of obesity and overweight. In Phase 2 trials, it demonstrated significant weight reduction, with participants losing up to nearly 30% of their body weight at the highest doses over 48 to 68 weeks.
• Type 2 Diabetes (T2DM): It is being studied for its ability to improve glycemic control by lowering HbA1c levels and managing blood sugar.
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/MASH):Formerly known as non-alcoholic fatty liver disease (NAFLD), trials have shown it can reduce liver fat by over 80%, potentially reversing fatty liver disease in a majority of patients.
• Knee Osteoarthritis: Specific Phase 3 trials (TRIUMPH-4) have evaluated its effectiveness in reducing pain and improving physical function in obese patients with knee osteoarthritis.
• Obstructive Sleep Apnea (OSA): Ongoing research is examining whether the significant weight loss it induces can improve symptoms of sleep apnea.
• Cardiovascular and Renal Health:Researchers are investigating its potential to reduce major adverse cardiovascular events (MACE) and protect kidney function in high-risk patients.